These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. ADP-ribosylation in Clostridium difficile toxin-treated cells is not related to cytopathogenicity of toxin B. Florin I; Thelestam M Biochim Biophys Acta; 1991 Jan; 1091(1):51-4. PubMed ID: 1995067 [TBL] [Abstract][Full Text] [Related]
11. Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Wedel N; Toselli P; Pothoulakis C; Faris B; Oliver P; Franzblau C; LaMont T Exp Cell Res; 1983 Oct; 148(2):413-22. PubMed ID: 6628564 [TBL] [Abstract][Full Text] [Related]
12. Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Genisyuerek S; Papatheodorou P; Guttenberg G; Schubert R; Benz R; Aktories K Mol Microbiol; 2011 Mar; 79(6):1643-54. PubMed ID: 21231971 [TBL] [Abstract][Full Text] [Related]
13. Difference in the cytotoxic effects of toxin B from Clostridium difficile strain VPI 10463 and toxin B from variant Clostridium difficile strain 1470. Huelsenbeck J; Dreger S; Gerhard R; Barth H; Just I; Genth H Infect Immun; 2007 Feb; 75(2):801-9. PubMed ID: 17145947 [TBL] [Abstract][Full Text] [Related]
14. Purification and characterisation of two forms of toxin B produced by Clostridium difficile. Torres JF; Lönnroth I FEBS Lett; 1988 Jun; 233(2):417-20. PubMed ID: 3133248 [TBL] [Abstract][Full Text] [Related]
15. Role of p38 Schelle I; Bruening J; Buetepage M; Genth H Toxins (Basel); 2016 Dec; 9(1):. PubMed ID: 28025502 [TBL] [Abstract][Full Text] [Related]
16. Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. Chaves-Olarte E; Weidmann M; Eichel-Streiber C; Thelestam M J Clin Invest; 1997 Oct; 100(7):1734-41. PubMed ID: 9312171 [TBL] [Abstract][Full Text] [Related]
17. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. Stubbe H; Berdoz J; Kraehenbuhl JP; Corthésy B J Immunol; 2000 Feb; 164(4):1952-60. PubMed ID: 10657645 [TBL] [Abstract][Full Text] [Related]
18. Purification and characterisation of toxin B from a strain of Clostridium difficile that does not produce toxin A. Torres JF J Med Microbiol; 1991 Jul; 35(1):40-4. PubMed ID: 1906544 [TBL] [Abstract][Full Text] [Related]
19. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797 [TBL] [Abstract][Full Text] [Related]